Citius Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Citius Pharmaceuticals, Inc. on June 13, 2017, covering events occurring on June 7 and June 8, 2017. The filing details the entry into material definitive agreements to modify restrictions on future financings stemming from a private placement completed in February 2017.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and financing agreements.
Material Changes and Agreements
- Release Agreement with Placement Agent: On June 7, 2017, the Company entered into a Release Agreement with Garden State Securities, Inc. (GSS). GSS waived covenants restricting the Company from selling securities below a $6.00 per share price limit (adjusted for a reverse stock split). In exchange, the Company issued 100,000 shares of restricted common stock to GSS.
- Release Agreements with Investors: On June 8, 2017, the Company entered into agreements with investors from the February 2017 Private Offering to release the Company from the same pricing restrictions.
- Investor Consideration: In exchange for the release, the Company agreed to:
- Issue additional shares to investors if a future "Uplisting Financing" occurs at a price lower than the $6.00 limit to effectively reprice the sale.
- Reduce the exercise price of warrants (originally $8.25 per share) to the lower financing price if the new price is below the warrant exercise price.
- Provide investors with a 6-hour notice and a 6-hour option to purchase up to 20% of securities in any subsequent financing.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on operations, or specific risk factors beyond the terms of the agreements. The primary contingency described is the potential dilution of existing shareholders or adjustment of warrant prices should the Company secure future financing at a price below the $6.00 threshold.
Key Facts for Investor Verification
- Verify the impact of the 100,000 shares issued to GSS on current share count and dilution.
- Confirm the adjusted price limits ($6.00 per share) and warrant exercise prices ($8.25 per share) following the reverse stock split effected on June 9, 2017.
- Review the full text of the Release Agreements (Exhibits 10.1 and 10.2) to understand the complete scope of the "Uplisting Financing" definition and the 20% investor option rights.
- Assess the likelihood of future financings occurring below the $6.00 price limit, which would trigger additional share issuances or warrant repricing.